US FDA approval for CAL056 Mesylate was granted on October 16th, 2020 to conduct Phase I clinical trial in US. The trial will be conducted in Texas and California. It is a great step forward for Calgent in new drug development.
©2026 Calgent Biotechnology Co. Ltd. All rights reserved. 網頁設計公司：振作國際